HIV Drug Reduces Carbon Emissions

A groundbreaking report has revealed that changing the ingredients or manufacturing methods of widely used medications can significantly reduce carbon emissions.

The study found a reduction of 26 million tons of CO2, equivalent to the entire carbon footprint of Geneva for ten years. This reduction has already been achieved.

The HIV treatment dolutegravir (DTG) is used by 24 million people worldwide. Over 110 low and middle-income countries have adopted DTG as the preferred treatment option. Rapid voluntary licensing of the medicine, including its pediatric version, to over a dozen generic manufacturers, has significantly reduced prices. It’s estimated that 1.1 million lives will be saved from HIV/AIDS-related deaths by 2027.

DTG’s predecessor, efavirenz, contained 1200 milligrams of active ingredients, while DTG contains 650 milligrams of just one compound. This small difference was enough to reduce the medication’s carbon footprint by a factor of 2.6.

Unitaid, a global public-private partnership that invests in new health products for low and middle-income countries, published the report “Milligrams to Megatons.” It is the first research to compare carbon footprints between commonly used medications. The authors noted that the reduction in carbon footprint surpasses many climate mitigation achievements in health and other sectors.

Since DTG entered production in 2017, 2.6 million fewer tons of CO2 have entered the atmosphere each year compared to if efavirenz was still the standard treatment. The global medical sector’s carbon emissions are about 5% of the global total, larger than the emissions of many big countries and 2.5 times as much as aviation.

“This report shows that we can achieve significant health improvements while also reducing carbon emissions. By adopting innovative practices and prioritizing sustainability, we can ensure that medicines like DTG are effective and environmentally responsible,” Vincent Bretin, Director of Unitaid’s Results and Climate Team, told Health Policy Watch.

Diabetes-Reversing Drug

In a new study published in Science Translational Medicine, A new drug tested in mice increased the number of beta cells in the pancreas sevenfold, effectively reversing diabetes symptoms.

This achievement, described as a “functional diabetes cure,” is unprecedented in drug development.

In just three months, the mice’s cells began producing insulin again through a combination of two drugs: harmine, which inhibits the enzyme DYRK1A, and a GLP1 receptor agonist, found in the diabetes drug Ozempic.

Researchers from Mount Sinai and City of Hope tested their drug by injecting human beta cells into mice and then administering the treatment. The beta cells increased sevenfold in three months, with diabetes symptoms disappearing within a month after treatment stopped.

Previous attempts at this concept involved converting stem cells into human pancreas beta cells in vitro and transplanting them into diabetes patients, a costly and time-consuming procedure.

“This is the first time scientists have developed a drug treatment that increases adult human beta cell numbers in vivo,” said Dr. Adolfo Garcia-Ocaña, corresponding author of the study. “This research brings hope for future regenerative therapies to treat the hundreds of millions of people with diabetes.” Harmine alone has undergone a phase 1 clinical trial in humans for safety and tolerability, but DYRK1A inhibitors have not.

World’s First ‘Zero Waste’ Restaurant

Every year, one-third of the food produced for human consumption across the world is wasted.

But a restaurant in London, UK, is trying to tackle the issue by aiming to produce no waste for the landfill. As part of its zero waste mission, Silo uses a nose to tail and root to tip approach to cooking out of respect for nature.

Rare Genetic Mutation in Frogs

Scientists in Western Australia have discovered a blue tree frog, a deviation from the usual green caused by a rare genetic mutation.

The blue magnificent tree frog was found in the Charnley River-Artesian Range Wildlife Sanctuary in the Kimberley region, as per the Australian Wildlife Conservancy (AWC).

This marks the first recorded instance of a blue mutation in the magnificent tree frog, according to AWC. “We found it after dark, perched on a bench near our research center,” said AWC field ecologist Jake Barker.

“It was exciting. Magnificent tree frogs are already impressive, but seeing a blue one is a rare opportunity.”

This mutation is extremely rare, noted Jodi Rowley, curator of Amphibian and Reptile Conservation Biology at the Australian Museum. “Occasionally, a green frog lacks yellow pigment, resulting in a blue frog,” she said. “I’ve seen thousands of frogs over the years, and only one blue frog before, which wasn’t as striking as this one.”

The magnificent tree frog, or Litoria splendida, is native to northern Kimberley and parts of the Northern Territory. It grows to about 12 centimeters (4.7 inches), making it one of Australia’s largest amphibians.

I think it is hilarious that they found right outside of their research center. They didn’t even have to go out looking for it.

Buoy to Protect Ocean-Life

During a routine clean-up by the non-profit Tangaroa Blue, GPS-tracking buoys were found washed up on Australian beaches. These buoys, manufactured in Spain by Satlink, were discovered in large numbers on the Cape York coast near Australia’s northeastern tip.

Instead of discarding them as e-waste, Tangaroa Blue founder Heidi Tait secured permission from Satlink to repurpose the buoys for tracking ‘ghost nets’—abandoned fishing nets that drift through the ocean, trapping sea life. These nets, often left behind after snagging on reefs or being displaced by weather, pose a significant threat to marine life and require specialized equipment to remove.

Tait organized a coalition of Australian mariners, including national park staff, Indigenous rangers, commercial fishermen, and charter boats, to use the buoys for tracking these ghost nets. By attaching a buoy to a found net, they can be precisely located and retrieved.

Project ReCon, a collaboration between Satlink, Tangaroa Blue, and around 100 commercial fishing vessels, aims to address this issue. Supported by The Nature Conservancy and The Pacific Community, the project has expanded to eight countries. As a result, Tait and her coalition have already removed three ghost nets, including one over 3 metric tons, and a 150-foot-long mooring rope.